Mannkind Corporation (MNKD) — Analysis Summary
Mannkind Corporation (MNKD) has a market cap of $1.25B with year-over-year revenue growth of +22.2%. Net margin stands at 1.7%. The stock trades at a P/E ratio of -52.2.
Key Takeaways
- Revenue changed +22.2% year-over-year
- Net margin of 1.7%
- P/E ratio of -52.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, MNKD posted revenue growth of +22.2% and trades at a P/E of -52.2.
Mannkind Corporation (MNKD)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 10.2x — highly leveraged, potential refinancing risk
Interest coverage at 0.9x — earnings do not cover interest payments
Net income turned negative after a profitable prior period.
Shareholder equity is negative, which can signal balance-sheet stress.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
592
Headquarters
DANBURY, CT
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.